Jon Wigginton

Dr. Wigginton is a physician and scientist with expertise in cancer immunotherapy drug development. He has over 25 years of experience in clinical oncology, with leadership experience in both academia and industry. Dr. Wigginton is currently Chief Medical Officer of Cullinan Oncology, LLC. and an advisor to MPM Capital. Prior, he was Chief Medical Officer at MacroGenics, where he led the company’s clinical development programs. Dr. Wigginton also held leadership positions at Bristol Myers Squibb as Therapeutic Area Head in Immuno-Oncology for Early Clinical Research and as Executive Medical Director and Group Medical Director of Discovery Medicine-Clinical Oncology, and prior to that, Director of Clinical Oncology at Merck & Co. Dr. Wigginton has also served in several positions for the Society for Immunotherapy of Cancer (SITC), including President, Chair of Executive Council, Board of Directors, and leadership roles on various operating committees. Early in his career, Dr. Wigginton worked at the National Cancer Institute for over 14 years, and served as Head of the Investigational Biologics Section in the Center for Cancer Research (intramural program). Dr. Wigginton earned his M.D. from the University of Michigan.